I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring translational research data of enoblituzumab (also known as TJ271) and preclinical data of TJ-C64B will be presented at the American Association for Cancer Research (AACR)...
English Version of Hands-On Medical VR Developed. Exhibiting At SXSW 2022.
TOKYO, March 9, 2022 /PRNewswire/ -- Jolly Good Inc. (based in Chuo-ku, Tokyo, Japan; CEO: Kensuke Joji; hereafter "Jolly Good"), known for developing and providing medical VR solutions and digital therapeutics VR programs, has developed an English version of their VR medical hands-on tracking system. Known as "VR Hands-On," the software allows students and physicians to engage in medical...
Kusum Healthcare recognized as one of Best Places to Work in Philippines for 2022
MANILA, Philippines, March 9, 2022 /PRNewswire/ -- Kusum Healthcare, a leading tech-driven pharmaceutical group, has been recently awarded the Best Place to Work certification in Philippines for 2022. During the company assessment, 97% of employees recommended the organization illustrating the company's focus on creating a stand-out employee experience where everyone can do their best work. The certification was based on...
Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting
Posters Showcase Early-Stage Clinical and Preclinical Pipeline. Focus on ATG-037, ATG-018, ATG-022, ATG-012 and ATG-008. SHANGHAI and HONG KONG, March 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the publication of abstracts for five posters...
Pudu Robotics Helps Hong Kong Combat Covid-19 Pandemic
The firm once again participates in the fight against the pandemic by donating robots that support contactless delivery and automatic disinfection SHENZHEN, China, March 9, 2022 /PRNewswire/ -- Pudu Robotics, the global leader in commercial service robots, has donated several of its BellaBot and Puductor 2 robots to Hong Kong to help the region address the severe outbreak of omicron...
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma
- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/or refractory multiple myeloma, a new treatment option. - XPOVIO®, in combination with dexamethasone (Xd), gives patients with triple class refractory multiple myeloma, a new treatment option. These patients have poor prognosis and limited treatment options. - XPOVIO®...
Cappfinity and Lexxic partnership helps organisations embrace neurodiversity in the workplace
LONDON, March 9, 2022 /PRNewswire/ -- HR tech firm, Cappfinity, has announced a new partnership with specialist neurodiversity consultancy, Lexxic, to help businesses create a culture that enables neurodivergent talent to flourish. Operating since 2007, Lexxic was founded by Chartered Occupational Psychologist Nicola James after experiencing the challenges of her own Dyslexia in the corporate sector. Neurodiversity refers to...
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting
New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipeline that transforms cancer immunotherapy leveraging company's AI-powered platform - SAFEbody® precision masking technology integrated across antibody-based modalities in POWERbody® candidates, designed to further enhance efficacy with secured safety - Data show safe, powerful and durable immunotherapy for solid tumors can be achieved through...
Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022
SUZHOU, China, March 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from phase II clinical study (KN026-203) of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) will be presented by E- poster at the 113th American Association for Cancer Research (AACR 2022) held from April 8-13, 2022. Founded in 1907, the American Association...
Notifyre utilises blockchain to transition healthcare communications away from fax
Proprietary SmartRoutingTM technology paves a path to messaging interoperability SUNSHINE COAST, Australia, March 9, 2022 /PRNewswire/ -- Notifyre, a multi-channel communications platform, launches its new SmartRouting feature built for transitional messaging. SmartRouting connects legacy messaging channels like fax, to more secure, reliable, and interoperable messaging systems like blockchain-audited encrypted file transfer, allowing users to make the transition in their...
